PEN-866 in Patients With Advanced Solid Malignancies

February 16, 2022 updated by: Tarveda Therapeutics

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Phase 1a will employ an adaptive model guided with overdose control principle to make dose recommendations and estimate the maximum tolerated dose (MTD) of PEN-866 (single agent).

Phase 1b will employ a standard 3 + 3 design to make dose recommendations and estimate the MTD of PEN-866 in combination therapy.

Phase 2a (single agent) will assess the safety, tolerability, pharmacokinetic, and pharmacodynamics profile of PEN-866 (single agent) at the recommended Phase 2 dose determined at the conclusion of Phase 1a in patients with advanced solid malignancies.

Study Type

Interventional

Enrollment (Anticipated)

340

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Arkansas
      • Springdale, Arkansas, United States, 72762
        • Recruiting
        • Highlands Oncology Group
    • Colorado
      • Denver, Colorado, United States, 80218
        • Recruiting
        • Sarah Cannon Reasearch Institute at HealthONE
    • Florida
      • Fort Myers, Florida, United States, 33901
        • Recruiting
        • Florida Cancer Specialists - South
      • Saint Petersburg, Florida, United States, 33705
        • Recruiting
        • Florida Cancer Specialists - North
      • West Palm Beach, Florida, United States, 33401
        • Recruiting
        • Florida Cancer Specialists - East
    • Maryland
      • Bethesda, Maryland, United States, 20892
        • Recruiting
        • National Institutes of Health / National Cancer Institute
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford
    • Nebraska
      • Omaha, Nebraska, United States, 68130
        • Recruiting
        • Nebraska Cancer Specialists
    • Nevada
      • Las Vegas, Nevada, United States, 89169
        • Recruiting
        • Comprehensive Cancer Centers of Nevada
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Recruiting
        • Stephenson Cancer Center, University of Oklahoma
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Recruiting
        • Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
    • South Carolina
      • Greenville, South Carolina, United States, 29605
        • Recruiting
        • Prisma Health - Upstate
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • Recruiting
        • The West Clinic
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Tennessee Oncology
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • Medical College of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. M/F at least 18 years old
  2. Performance status 0 or 1
  3. Adequate bone marrow, liver, and kidney function within 28 days prior to first dose
  4. Serum potassium, calcium, magnesium, phosphorus within normal limits
  5. Adequate birth control
  6. Central venous access line is required
  7. Patients in Phase 1a must also have confirmed advanced solid malignancy that has progressed after one or more prior lines of anticancer therapy and no other standard of care therapies that are deemed appropriate for treatment of their malignancy
  8. Patients in Phase 2a must have measurable disease per RECIST 1.1 and documented disease progression during or after their most recent line of anticancer therapy.

  9. Patients in Phase 2a must have disease history specific to their disease as listed below:

    • Small Cell Lung Cancer (SCLC): Patients with locally recurrent or metastatic SCLC whose disease has progressed after having received one or more prior lines of chemotherapy.
    • Gastric or gastroesophageal (GEJ) adenocarcinoma: Patients with locally recurrent or metastatic gastric or GEJ adenocarcinoma whose disease has progressed after having received one or more prior lines of chemotherapy.
    • Squamous cell carcinoma (SCC) of the genitalia (anus, cervix, vulva, or penis): Patients with locally recurrent or metastatic SCC of the genitalia (anus, cervix, vulva, or penis) whose disease has progressed after having received one or more prior lines of chemotherapy, including those whose disease has progressed after postoperative adjuvant chemotherapy or neoadjuvant chemotherapy prior to radiation or surgery.
    • Pancreatic adenocarcinoma (PDAC): Patients with locally recurrent or metastatic PDAC whose disease has progressed after having received one or more prior lines of chemotherapy, including those whose disease has progressed within 6 months of postoperative adjuvant chemotherapy.
    • Endometrial adenocarcinoma (EC): Patients with locally recurrent or metastatic EC whose disease has progressed after having received one or more prior lines of chemotherapy, including those whose disease has progressed within 6 months of postoperative adjuvant chemotherapy.

  10. For Phase 1b patients receiving PEN-866 in combination with fluorouracil and folinic acid only:

    • Patients with metastatic PDAC who have progressed after having received one or more prior lines of chemotherapy, including those whose disease has progressed within 6 months of postoperative adjuvant chemotherapy.

  11. For Phase 1b patients receiving the Niraparib combination only:

    • Patients must have confirmed advanced solid malignancy that has progressed after one or more prior lines of anticancer therapy and no other standard of care therapies that are deemed appropriate for treatment of their malignancy

Exclusion Criteria:

  1. Treatment with anticancer therapy or investigational drug or device within 2 wk (6 wk for nitrosureas or mitomycin C) before C1D1, and any drug-related toxicities must have recovered to grade 1 or less with the exception of alopecia and peripheral neuropathy.
  2. Phase 2a only: Prior treatment with topoisomerase I inhibitor(s).

  3. Cardiac disease such as unstable angina within 6 months of screening, myocardial infarction within 6 months of screening, NY Heart Association Class III - IV heart failure, QTc greater than 470 msec, congenital long Qt syndrome, symptomatic orthostatic hypotension within 6 months of screening, uncontrolled hypertension, or clinically important abnormalities in heart rhythm, conduction, morphology of resting ECG.

    -For Phase 1b patients receiving the Niraparib combination only: hypertension as defined as diastolic > 90 mmHg or systolic > 140 mmHg

  4. Stroke or transient ischemic attack within 6 months of screening
  5. Prior history of posterior reversible excephalopathy scyndrome (PRES).
  6. Peripheral neuropathy greater than grade 2
  7. Patients requiring medications with drugs that are inhibitors of UGT1A1 or substrates of CYP1A2, P-gP, BCRP, OATP1B1, OATP1B3 or OCT1 transporters
  8. Leptomeningeal disease or spinal cord compression unless controlled and asymptomatic with surgery, radiation, and not requiring steroids within 4 weeks prior to C1D1.
  9. Brain metastases unless previously treated and asymptomatic. Stable low dose of steroids is permitted.
  10. Major surgery within 28 days of first drug dose
  11. If female, pregnant or breast feeding
  12. Evidence of severe uncontrolled systemic disease, bleeding diatheses, renal or liver transplant, active infection with hep B or C or HIV
  13. Hypersensitivity or anaphylactic reaction to ganetespib or other HSP90 inhibitors, irinotecan, SN-38 or its derivatives
  14. Any medical, psychological, or social condition that would interfere with the patient's participation in the study.
  15. Live virus and bacterial vaccines administered within 30 days prior to C1D1.

  16. Any medical, psychological, or social condition that would interfere with the patient's participation in the study.

    For Phase 1b patients receiving niraparib combination only, the following additional exclusion criteria apply:

  17. Prior treatment with niraparib.
  18. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastatses or otherwise stable chronic liver disease per investigator assessment).
  19. Severe hepatic impairment.
  20. Treatment with transfusions and/or erythropoietin for the treatment of anemia within 4 weeks prior to C1D1.
  21. Any known or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  22. History of prostate cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NON_RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Phase 1a PEN-866 Sodium (Single Agent)
Dose escalation of PEN-866 Sodium administered intravenously
Drug: PEN-866 Sodium
PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
EXPERIMENTAL: Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid
Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
Drug: PEN-866 Sodium
PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
Drug: fluorouracil
Fluorouracil 2400 mg/m2 IV
Other Names:
  • 5-FU
  • 5-Fluorouracil
Drug: Folinic acid
Folinic acid 400 mg/m2 IV
Other Names:
  • Leucovorin
EXPERIMENTAL: Phase 2a PEN-866 Sodium (Single Agent)
Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
Drug: PEN-866 Sodium
PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
EXPERIMENTAL: Phase 1b PEN-866 Sodium + Niraparib
Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
Drug: PEN-866 Sodium
PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
Drug: Niraparib
Niraparib
Other Names:
  • Zejula

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 1a and 1b : Incidence of Dose-Limiting Toxicities (DLTs)
Time Frame: Patients will be followed for 28 days to determine the incidence of DLTs.
The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) will be determined by assessing the incidence of DLTs and treatment related adverse events of PEN-866 as a single agent (Phase 1a) or in combination therapy (Phase 1b).
Patients will be followed for 28 days to determine the incidence of DLTs.
All Phases: Incidence of treatment related adverse events (Safety and tolerability)
Time Frame: From date of first treatment/trial entry up to 28 days following the last treatment.
Safety and tolerability will be determined by assessing the incidence of treatment related adverse events.
From date of first treatment/trial entry up to 28 days following the last treatment.
Phase 2a: Efficacy of PEN-866 in patients with SCLC using best overall response rate
Time Frame: From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in patients with SCLC will be assessed using best overall tumor response rate defined as complete response (CR) or partial response (PR) according to RECIST 1.1.
From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Efficacy of PEN-866 in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma using best overall response rate
Time Frame: From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in patients with gastric or GEJ adenocarcinoma will be assessed using best overall tumor response rate defined as CR or PR according to RECIST 1.1.
From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Efficacy of PEN-866 in patients with pancreatic adenocarcinoma using Disease Control Rate (DCR)
Time Frame: From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in patients with pancreatic adenocarcinoma will be assessed using DCR defined as a best response of CR, PR, or stable disease (SD) according to RECIST 1.1.
From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Efficacy of PEN-866 in patients with endometrial adenocarcinoma using best overall response rate
Time Frame: From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in patients with endometrial adenocarcinoma will be assessed using best over all tumor response rate defined as CR or PR according to RECIST 1.1.
From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate
Time Frame: From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia will be assessed using best over all tumor response rate defined as CR or PR according to RECIST 1.1.
From the date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum concentration (Cmax) of PEN-866 and its components (HSP90 ligand and SN-38)
Time Frame: 1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Characterize the pharmacokinetic properties of PEN-866 and its components (HSP90 targeting ligand and SN-38)
1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Area under the curve (AUC) of PEN-866 and its components (HSP90 ligand and SN-38)
Time Frame: 1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Characterize the pharmacokinetic properties of PEN-866 and its components (HSP90 targeting ligand and SN-38)
1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Half-life (t1/2) of PEN-866 and its components (HSP90 ligand and SN-38)
Time Frame: 1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Characterize the pharmacokinetic properties of PEN-866 and its components (HSP90 targeting ligand and SN-38)
1 Month (Phase 1a); 14 days (Phase 1b); assessed up to (estimated) 18 months for Phase 2a
Phase 1b: Characterize the plasma pharmacokinetics (PK) of the combination therapies and their components
Time Frame: 14 days
PK parameters (CMax, AUC) will be evaluated in plasma by standard non-compartmental methods (compartmental modeling may be performed if appropriate).
14 days
Phase 1a: Tumor response using RECIST 1.1 criteria
Time Frame: Baseline and every 6 weeks until date of first documented progression or death (estimated 6 months)
Size of tumors by CT or MRI using tumor response criteria according to RECIST 1.1 and duration of response.
Baseline and every 6 weeks until date of first documented progression or death (estimated 6 months)
Phase 1b: Disease Control Rate
Time Frame: From date of first treatment through the date of date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in combination therapy will be assessed using DCR as defined as CR, PR, or SD according to RECIST 1.1.
From date of first treatment through the date of date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Disease Control Rate in patients with SCLC, gastric or gastroesophageal junction adenocarcinoma, endometrial adenocarcinoma, and squamous cell carcinoma of the genitalia (anus, cervix, vulva, and penis)
Time Frame: From date of first treatment through the date of date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in SCLC, gastric or gastroesophageal junction adenocarcinoma, endometrial adenocarcinoma, and squamous cell carcinoma of the genitalia (anus, cervix, vulva, and penis) will be assessed using DCR as defined as CR, PR, or SD according to RECIST 1.1.
From date of first treatment through the date of date of first documented progression, assessed up to (estimated) 18 months
Phase 2a: Evaluate the best overall response rate in patients with pancreatic adenocarcinoma
Time Frame: From date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Efficacy of PEN-866 in pancreatic adenocarcinoma using best overall tumor response rate as defined as CR or PR according to RECIST 1.1
From date of first treatment through the date of first documented progression, assessed up to (estimated) 18 months
Phase 1b and 2a: Duration of Response
Time Frame: From date of first treatment until the date of date of death from any cause, assessed up to (estimated) 18 months
Time from first documented response (CR or PR) to date of first documented disease progression or death due to underlying cancer.
From date of first treatment until the date of date of death from any cause, assessed up to (estimated) 18 months
Phase 2a: Radiographic progression free survival
Time Frame: From date of first treatment until the date of first documented progression or date of death from any cause, whichever is first, assessed up to (estimated) 18 months
Time from first PEN-866 dose to date of first documented progression or date of death from any cause, whichever came first
From date of first treatment until the date of first documented progression or date of death from any cause, whichever is first, assessed up to (estimated) 18 months
Phase 2a: Overall survival
Time Frame: From date of first treatment until the date of date of death from any cause, assessed up to (estimated) 18 months
Time from first PEN-866 dose to date of death from any cause
From date of first treatment until the date of date of death from any cause, assessed up to (estimated) 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tarveda Therapeutics

Investigators

  • Study Chair: Anish Thomas, MD, National Cancer Institute (NCI)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 29, 2017

Primary Completion (ANTICIPATED)

January 1, 2023

Study Completion (ANTICIPATED)

June 1, 2023

Study Registration Dates

First Submitted

July 13, 2017

First Submitted That Met QC Criteria

July 17, 2017

First Posted (ACTUAL)

July 18, 2017

Study Record Updates

Last Update Posted (ACTUAL)

February 17, 2022

Last Update Submitted That Met QC Criteria

February 16, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PEN-866-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on PEN-866 Sodium

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe